Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?
Authors: Nirav N. Shah, Mehdi Hamadani
Journal: Journal of Clinical Oncology (2021)

Article Tools REVIEW ARTICLES Immunotherapy for Hematologic Malignancies Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.20.01447 Journal of Clinical Oncology - published online before print January 12, 2021 PMID: 33434076 Is There Still a Role for Allogeneic Transplantation in the Management of Lymphoma? Nirav N. Shah, MD, MS1xNirav N. ShahSearch for articles by this author and Mehdi Hamadani, MD1,2xMehdi HamadaniSearch for articles by this author Show More 1Blood and Bone Marrow Transplant and Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, WI2Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI https://doi.org/10.1200/JCO.20.01447 First Page Full Text PDF Figures and Tables © 2021 by American Society of Clinical OncologyCONTEXTKey ObjectiveThis review critically analyzes the role of allogeneic transplantation in the management of lymphomas in the current era of novel immunotherapies.Knowledge GeneratedNovel immunotherapies are challenging the role of allogeneic transplantation in lymphomas in general and B-cell non-Hodgkin lymphoma (NHL) in particular. In regions with access to chimeric antigen receptor T-cell therapies (CAR-Ts), allogeneic transplant for diffuse large B-cell lymphoma and mantle cell lymphoma will likely be restricted to relapse after CAR-T or for patients who are not good candidates for CAR-T. In patients with high-risk or relapsed T-cell NHL and patients with classic Hodgkin lymphoma and triple refractory disease, allogeneic transplantation remains a viable, curative option.RelevanceThe review redefines the current clinical scenarios where allogeneic transplantation should be considered in the management of patients with lymphoma.AUTHOR CONTRIBUTIONSConception and design: All authorsCollection and assembly of data: All authorsData analysis and interpretation: All authorsManuscript writing: All authorsFinal approval of manuscript: All authorsAccountable for all aspects of the work: All authorsAUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTIs There Still a Role for Allogeneic Transplantation in the Management of Lymphoma?The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Nirav N. ShahStock and Other Ownership Interests: Exelixis, Oncosec, Geron, Cidara Therapeutics, Cell VaultHonoraria: Miltenyi BiotecConsulting or Advisory Role: Kite Pharma, Incyte, Juno Therapeutics, Celgene, VerastemResearch Funding: Miltenyi BiotecTravel, Accommodations, Expenses: Miltenyi BiotecMehdi HamadaniHonoraria: CelgeneConsulting or Advisory Role: MedImmune, Cellerant Therapeutics, Janssen Research & Development, Incyte, Pharmacyclics, ADC Therapeutics, Puma Biotechnology (I), VerastemSpeakers’ Bureau: Genzyme, Celgene, AstraZenecaResearch Funding: Takeda Pharmaceuticals, Spectrum Pharmaceuticals, Otsuka US, Astellas Pharma, GenzymeNo other potential conflicts of interest were reported.